Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours

References

• Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25–38.
   PubMed Web of Science ®Google Scholar
• Grodzinski P, Farrell D. Future opportunities in cancer nanotechnology-NCI strategic workshop report. Cancer Res. 2014;74:1307–1310.
   PubMed Web of Science ®Google Scholar
• Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research–view from NCI Alliance for Nanotechnology in Cancer. Biotechnol Adv. 2014;32:666–678.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Simberg D. Opening windows into tumors. ACS Nano. 2015;9:8647–8650.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
   PubMed Web of Science ®Google Scholar
• Smith BR, Kempen P, Bouley D, et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 2012;12:3369–3377.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Simberg D. Nanoparticle transport pathways into tumors. J Nanopart Res. 2018;20:169.
   PubMed Web of Science ®Google Scholar
• Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998;101:1401–1413.
   PubMed Web of Science ®Google Scholar
• Liu X, Lin P, Perrett I, et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest. 2017;127:2007–2018.
   PubMed Web of Science ®Google Scholar
• Dvorak AM, Feng D. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem. 2001;49:419–432.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotech. 2007;2:47–52.
   PubMed Web of Science ®Google Scholar
• Chen F, Hong H, Shi S, et al. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep. 2014;4:5080.
   PubMed Web of Science ®Google Scholar
• Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14:972–981.
   PubMed Web of Science ®Google Scholar
• Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA. 2007;104:932–936.
   PubMed Web of Science ®Google Scholar
• Goel S, Chen F, Hong H, et al. VEGF(1)(2)(1)-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces. 2014;6:21677–21685.
   PubMed Web of Science ®Google Scholar
• ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15:1973–1980.
   PubMed Web of Science ®Google Scholar
• Yang L, Peng XH, Wang YA, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res. 2009;15:4722–4732.
   PubMed Web of Science ®Google Scholar
• Huang X, Peng X, Wang Y, et al. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010;4:5887–5896.
   PubMed Web of Science ®Google Scholar
• Sykes EA, Chen J, Zheng G, et al. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano. 2014;8:5696–5706.
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198–205.
   PubMed Web of Science ®Google Scholar
• Choi CH, Alabi CA, Webster P, et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA. 2010;107:1235–1240.
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861–2871.
   PubMed Web of Science ®Google Scholar
• Hussain S, Rodriguez-Fernandez M, Braun GB, et al. Quantity and accessibility for specific targeting of receptors in tumours. Sci Rep. 2014;4:5232.
   PubMed Web of Science ®Google Scholar
• Frieboes HB, Wu M, Lowengrub J, et al. A computational model for predicting nanoparticle accumulation in tumor vasculature. PLoS One. 2013;8:e56876.
   PubMed Web of Science ®Google Scholar
• Schluep T, Hwang J, Hildebrandt IJ, et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci USA. 2009;106:11394–11399.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotech. 2012;7:383–388.
   PubMed Web of Science ®Google Scholar
• Wang H, Gao H, Guo N, et al. Site-specific labeling of scVEGF with fluorine-18 for positron emission tomography imaging. Theranostics. 2012;2:607–617.
   PubMed Web of Science ®Google Scholar
• Zeng X, Zhang Y, Nystrom AM. Endocytic uptake and intracellular trafficking of bis-MPA-based hyperbranched copolymer micelles in breast cancer cells. Biomacromolecules. 2012;13:3814–3822.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16:510–520.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664.
   PubMed Web of Science ®Google Scholar
• Kording F, Weidensteiner C, Zwick S, et al. Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis. J Magn Reson Imaging. 2014;40:1310–1318.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Goel S, Chen F, Luan SJ, et al. Engineering Intrinsically Zirconium-89 Radiolabeled Self-Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies. Adv Sci. 2016;3.
   Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010.
   PubMed Web of Science ®Google Scholar
• Zhou H, Fan Z, Deng J, et al. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 2016;16:3268–3277.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.
   PubMed Web of Science ®Google Scholar
• Perrault SD, Walkey C, Jennings T, et al. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9:1909–1915.
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118–129.
   PubMed Web of Science ®Google Scholar
• Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA. 1995;92:8999–9003.
   PubMed Web of Science ®Google Scholar
• Ramezanpour M, Leung SS, Delgado-Magnero KH, et al. Computational and experimental approaches for investigating nanoparticle-based drug delivery systems. Biochim Biophys Acta. 2016;1858:1688–1709.
   PubMed Web of Science ®Google Scholar
• Duncan GA, Bevan MA. Computational design of nanoparticle drug delivery systems for selective targeting. Nanoscale. 2015;7:15332–15340.
   PubMed Web of Science ®Google Scholar
• Miao L, Newby JM, Lin CM, et al. The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors. ACS Nano. 2016.
   Web of Science ®Google Scholar
• Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater. 2014;13:125–138.
   PubMed Web of Science ®Google Scholar
• Dai Q, Wilhelm S, Ding D, et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano. 2018;12:8423–8435.
   PubMed Web of Science ®Google Scholar
• Choi I-K, Strauss R, Richter M, et al. Strategies to increase drug penetration in solid tumors. Front Oncol. 2013;3:193.
   PubMedGoogle Scholar
• Roth L, Agemy L, Kotamraju VR, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene. 2012;31:3754–3763.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031–1035.
   PubMed Web of Science ®Google Scholar
• Key J, Palange AL, Gentile F, et al. Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors. ACS Nano. 2015;9:11628–11641.
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5:496–504.
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Impact of particle elasticity on particle-based drug delivery systems. Adv Drug Deliv Rev. 2016.
   Web of Science ®Google Scholar
• Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One. 2010;5:e10051.
   PubMed Web of Science ®Google Scholar
• Wang G, Griffin JI, Inturi S, et al. In vitro and in vivo differences in murine third complement component (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms. Front Immunol. 2017;8:151.
   PubMed Web of Science ®Google Scholar
• Lin A, Sabnis A, Kona S, et al. Shear-regulated uptake of nanoparticles by endothelial cells and development of endothelial-targeting nanoparticles. J Biomed Mater Res. 2010;93:833–842.
   Google Scholar
• Imoukhuede PI, Popel AS. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med. 2014;3:225–244.
   PubMed Web of Science ®Google Scholar
• Miller MA, Zheng YR, Gadde S, et al. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun. 2015;6:8692.
   PubMed Web of Science ®Google Scholar
• Dawidczyk CM, Russell LM, Searson PC. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem. 2014;2:69.
   PubMed Web of Science ®Google Scholar
• Liang M, Liu X, Cheng D, et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjugate Chem. 2010;21:1385–1388.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.
   Web of Science ®Google Scholar